Patented and Scientifically Proven Creatine Derivative Supplement Preparation for Sale by ICAP Patent Brokerage

Jan 22, 2013, 06:00 ET from ICAP Patent Brokerage

CHICAGO, Jan. 22, 2013 /PRNewswire/ -- ICAP Patent Brokerage announces for sale a patented and thoroughly studied preparation for the creatine analogue Cyclocreatine Phosphate from Nour Heart, Inc., which is formulated as a dietary supplement and offers cardioprotection and energy support.


Creatine is a naturally occurring compound necessary for muscle contraction. When administered, the Cyclocreatine Phosphate supplement improves athletic performance by giving skeletal muscles more energy and slowing muscle fatigue while protecting heart tissues and supporting faster recovery. The compound delivers results via a safe, water-soluble supplement that is easily absorbed and provides smaller dosage requirements without harsh side effects. This is an important IP package for companies involved in the production of sports supplements, athletic performance beverages, nutritional supplement protein drinks, and healthcare products.

"We are excited to offer this novel Cyclocreatine Phosphate supplement to our global base of buyers. Patented, with years of study to support its claims, this is the next generation of dietary supplements for the health-conscious looking for safe and effective energy and cardioprotection aids," says Dean Becker, CEO of ICAP Patent Brokerage.

Key Characteristics & Benefits

The portfolio for sale describes a method of preparation that produces a much more stable compound of Cyclocreatine Phosphate than is currently available. This altered Cyclocreatine Phosphate's advantage over other supplements is two-fold: it is water-soluble, so the required effective dose can be cut in half, resulting in significant reduction in its side effects; and it can be used as a dietary supplement. Empirical studies have shown that Cyclocreatine Phosphate is known to significantly improve the performance of athletes by providing skeletal muscles with more energy, thus slowing muscle fatigue.

Further, due to its water-soluble properties it can be taken both orally and by injection unlike its non-soluble alternative Cyclocreatine, which is only for oral use. The patented Cyclocreatine Phosphate can also be synthesized from cost-effective ingredients into a stable form. Given its high stability it can be directly added to sports and nutritional drinks.

This innovative cardioprotection supplement is applicable to a wide range of groups – from athletes wishing to boost energy to high-risk healthcare constituencies such as patients with coronary artery disease, high blood pressure, diabetics, cancer, obesity, and those at risk of heart attack. The administration of this supplement before the initiation of medical traumas such as heart attack can have a significant cardioprotection effect and preserve and restore cardiac function.

The technical description of this IP sales offering includes information regarding the referenced studies, specific medical agents employed, and further applications for the invention.

To learn more about the assets available for sale in this portfolio:
Contact Dean Becker of ICAP Patent Brokerage at (561) 309-0011 or via email at

Follow us on Twitter (@ICAP_Auction_IP) and join our LinkedIn group.

About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.

About ICAP
ICAP is the world's leading interdealer broker and provider of post trade risk and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, go to

SOURCE ICAP Patent Brokerage